[Sleep apnea synrome : effects of chlorimipramine in subjects with stable body weight (author's transl)].
Beneficial effects have been attributed to Chlorimipramine in the treatment of sleep apnea syndrome (SAS). However, there were no quantitative evaluations of these effects. Polygraphic studies were made before and after chlorimipramine treatment (75 mg per day for 3 to 16 months). The 3 SAS subjects, whose weight remained stable throughout the course of treatment, showed no evidence of reduced hypopnea and apnea during sleep.
D000328:Adult; D002747:Chlorpropamide / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D012891:Sleep Apnea Syndromes / Q000188:drug therapy*
D002747:Chlorpropamide
Syndrome d'apnées au cours du sommeil; effet de la chlorimipramine chez des sujets à poids stable.